Fischer Medical Ventures Limited has informed the exchange on approval for proposed investment as detailed in the annexures to this announcement
FISCHER · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fischer Medical Ventures' Audit Committee, meeting on April 21, 2025, approved two equity investments by the company. The first is USD 1 million in cash for a 60% stake in Fischer Hospitality Sdn. Bhd, a newly incorporated Malaysian investment holding company that will become a foreign subsidiary and qualifies as a related-party transaction. The second is USD 0.5 million in cash for a 1.70% stake in Obelab Inc., a Korean medical device company with FY24 revenue of USD 1.6 million that makes brain imaging devices using NIRS technology for diagnosing mental health and neurological conditions. Under the deal, Fischer Medical Ventures will become Obelab's exclusive distributor in India, ASEAN, Africa and GCC countries, and non-exclusive elsewhere. Total committed cash outlay across both investments is USD 1.5 million.
The investments mark an early international expansion push, pairing a strategic distribution partnership in neurodiagnostic devices with a related-party overseas subsidiary, which shareholders may want to monitor for arm's-length fairness and future consolidation.